Treatment of Severe Hypercholesterolemia in Patients with Coronary Heart Disease by Means of Lipoprotein Apheresis

  • D. Seidel


Diseases resulting from premature atherosclerosis are the most common cause not only of death but also of early retirement [1-2]. Today, the major therapeutic interventions for atherosclerotic coronary disease are percutaneous transluminal coronary angioplasty and coronary bypass graft surgery (see chapter by F. Loop, this volume). At the time of these therapeutic interventions, however, the disease has already become clinically very relevant and, within its own natural history, is at a very late stage. Hence early risk factor intervention is of particular importance to prevent the disease. Nevertheless, even in patients who have undergone coronary bypass surgery, risk factor intervention, in particular treatment of hypercholesterolemia is crucial to maintain functionally vital grafts (see also chapter by H. Drexel and F. Amman, this volume).


Familial Hypercholesterolemia Familial Hypercholesterolemia Lipoprotein Apheresis Severe Hypercholesterolemia Percutaneous Trans Luminal Coronary Angioplasty 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Castelli WP, Wilson PWF, Levy D, Anderson K (1990) Serum lipids and risk of coronary artery disease. In: Leaf A, Weber PC (eds) Atherosclerosis reviews, vol 21. Raven, New York, pp 7–19.Google Scholar
  2. 2.
    Cremer P, Muche R (1990) Göttinger Risiko-, Inzidenz-und Prävalenzstudie (GRIPS) Empfehlungen zur Prävention der koronaren Herzkrankheit. Ther Umsch 6: 482–491.Google Scholar
  3. 3.
    Seidel D, Neumeier D, Cremer P, Nagel D (1992) Lipoprotein(a) in internal medicine. 9th international symposium on atherosclerosis, Rosemont-Chicago, 6–11 Oct 1991.Google Scholar
  4. 4.
    Koenig W, Ernst E (1992) The possible role of hemorrheology in atherothrombogenesis. Atherosclerosis 94(2,3): 93–107.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith EB (1990) Transport, interactions and retention of plasma proteins in the intima: the barrier function of the internal elastic lamina. Eur Heart J 11[Suppl E]: 72–81.PubMedGoogle Scholar
  6. 6.
    Smith EB (1986) Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. In: Fidge NH, Nestel PJ (eds) Atherosclerosis VI. Elsevier, Amsterdam, pp 459–462.Google Scholar
  7. 7.
    Kienast J, Berning B, van de Loo J (1990) Fibrinogen als Risikoindikator bei arteriosklerotischen Veränderungen und Koronararterien-Erkrankungen. Diagn Lab 40: 162.Google Scholar
  8. 8.
    Brown MS, Goldstein JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232: 34–37.PubMedCrossRefGoogle Scholar
  9. 9.
    Seidel D, Cremer P, Thiery J (1985) Plasmalipoproteine und Atherosklerose. Intern Welt 5: 114–124, 6: 159-165.Google Scholar
  10. 10.
    Cremer P, Nagel D, Labrot B, Muche R, Elster H, Mann H, Seidel D (1991) Göttinger Risiko-, Inzidenz-und Prävalenzstudie (GRIPS). Springer, Berlin Heidelberg New York.CrossRefGoogle Scholar
  11. 11.
    Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RT, Brand RJ, Gould KL (1990) Can lifestyle changes revers coronary heart disease? Lancet 336: 129–133.PubMedCrossRefGoogle Scholar
  12. 12.
    Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group (1990) Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 323: 946–955.PubMedCrossRefGoogle Scholar
  13. 13.
    Brown BG, Albers JJ, Fisher LD, Schaeffer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT (1990) Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289–1298.PubMedCrossRefGoogle Scholar
  14. 14.
    Blankenhorn D, Nessim S, Johnson R, Sanmarco ME, Azen SP et al. (1987) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257: 3233–3240.PubMedCrossRefGoogle Scholar
  15. 15.
    Gohlke H, Bestehorn H-P, Braunagel K, Bauer M, Betz P, Schuff-Werner P, Seidel D for the H.E.L.P. — Study Group (1992) H.E.L.P. — Therapie Lührt zu Regression der KHK bei patienten mit therapierefraktärer lamiliärer Hypercholesterinämie. Z Kardiol 81: 66.Google Scholar
  16. 16.
    Hennerici M, Kleophas W, Gries FA (1991) Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 22: 989–992.PubMedCrossRefGoogle Scholar
  17. 17.
    Buchwald H (1964) Lowering of cholesterol adsorption and blood levels by ileal exclusion. Circulation 29: 713–720.PubMedGoogle Scholar
  18. 18.
    Starzl TE, Chase HP, Ahrens EH, McNamara DJ, Bilheimer DW, Schaefer EF, Rey J, Porter KA, Stein E, Francavilia A, Benson LN (1983) Portocaval shunt in patients with familial hypercholesterolemia. Ann Surg 198: 273–283.PubMedCrossRefGoogle Scholar
  19. 19.
    Starzl LE, Bilheimer DW, Bahnson HT, Shaw BW, Hardesty RL, Griffith BP, Iwatsuki S, Zitelli BJ, Gartner JC, Malatack JJ, Urbach AH (1984) Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet 1: 1382–1383.PubMedCrossRefGoogle Scholar
  20. 20.
    De Gennes J, Touraine R, Maunard B et al. (1976) Formes homozygotes cutaneoten-dineuses de xanthomatose hypercholesterolemique dans une observation familiale exemplaire. Essai de plasmapherese à titre de traitement heroique. Bull Mem Soc Hop Paris 118: 1377–1402.Google Scholar
  21. 21.
    Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1: 1208–1211.PubMedCrossRefGoogle Scholar
  22. 22.
    Lupien PJ, Moojani S, Award J (1976) A new approach to the management of familial hyperchlesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1: 1261–1265.PubMedCrossRefGoogle Scholar
  23. 23.
    Stoffel W, Demant T (1981) Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. Proc Natl Acad Sci USA 78: 611–615.PubMedCrossRefGoogle Scholar
  24. 24.
    Riesen WT, Imhof C, Sturzenegger E, Descoeudres C, Mordasini R, Oetliker OH (1986) Behandlung der Hypercholesterinämie durch extrakorporale Immunabsorption. Schweiz Med Wochenschr 116: 8.PubMedGoogle Scholar
  25. 25.
    Yokoyama S, Hayashi R, Satani M, Yamamoto A (1985) Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Atherosclerosis 5: 613.Google Scholar
  26. 26.
    Seidel D, Wieland H (1982) Ein neues Verfahren zur selektiven Messung und extrakorporalen Elimination von Low-Density-Lipoproteinen. J Clin Chem Clin Biochem 20: 684–685.Google Scholar
  27. 27.
    Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D (1987) Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the H.E.L.P. system. Klin Wochenschr 65: 161–168.PubMedCrossRefGoogle Scholar
  28. 28.
    Armstrong VW (1987) DeDie säureinduzierte Präzipitation von Low-Density-Lipoproteinen mit Heparin. Grundlagen zum H.E.L.P.-Verfahren. Habilitationsschrift, Göttingen.Google Scholar
  29. 29.
    Seidel D (1990) The H.E.L.P. system: an efficient and safe method of plasmatherapy in the treatment of severe hypercholesterolemia. Ther Umsch 47: 514–519.PubMedGoogle Scholar
  30. 30.
    Würzner R, Schuff-Werner P, Franzke A, Nitze R, Oppermann M, Armstrong VW, Eisenhauer T, Seidel D, Götze O (1991) Complement activation and depletion during LDL-apheresis by heparin-induced extracorporeal LDL-precipitation (H.E.L.P.). Eur J Clin Invest 21: 288–294.PubMedCrossRefGoogle Scholar
  31. 31.
    Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D (1989) Effect of H.E.L.P.-LDL apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 19: 235–240.PubMedCrossRefGoogle Scholar
  32. 32.
    Thiery J, Walli AK, Janning G, Seidel D (1990) Low density lipoprotein plasmapheresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolemia. Eur J Pediatr 149: 716–721.PubMedCrossRefGoogle Scholar
  33. 33.
    Schuff-Werner P, Schütz E, Seyde WC, Eisenhauer T, Janning G, Armstrong VW, Seidel D (1989) Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (H.E.L.P.). Eur J Clin Invest 19: 30–37.PubMedGoogle Scholar
  34. 34.
    Kleophas W, Leschke M, Tschöpe D, Martin J, Schauseil S, Schottenfeld Y, Strauer BE, Gries FA (1990) Akute Wirkungen der extrakorporalen LDL-Cholesterin-und Fibrinogen-Elimination auf Blutrheologie und Mikrozirkulation. Dtsch Med Wochenschr 115: 7–11.CrossRefGoogle Scholar
  35. 35.
    Thiery J, Armstrong V, Bosch T, Eisenhauer T, Schuff-Werner P, Seidel D (1990) Maximaltherapy der Hypercholesterinämie bei koronarer Herzerkrankung. Ther Umsch 47(6): 520–529.PubMedGoogle Scholar
  36. 36.
    Seidel D, Armstrong VW, Schuff-Werner P for the H.E.L.P. Study Group (1991) The H.E.L.P.-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 21: 375–383.PubMedCrossRefGoogle Scholar
  37. 37.
    Schultis H-W, v Bayer H, Neitzel H, Riedel E (1990) Functional characteristics of LDL particles derived from various LDL-apheresis techniques regarding LDL-drug-complex preparation. J Lipid Res 31: 2277–2284.PubMedGoogle Scholar
  38. 38.
    Goldstein JL, Brown MS (1983) Familial hypercholesterolemia. In: Starnbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease. 5th Edition, McGraw-Hill, New York, pp 672–712.Google Scholar
  39. 39.
    Keller C (1991) LDL-apheresis: results of long-term treatment and vascular outcome. Atherosclerosis 86: 1–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Demant T, Seidel D (1992) Recent developments in low-density lipoprotein apheresis. Curr Opin Lipidol 3: 43–48.CrossRefGoogle Scholar
  41. 41.
    Gordon BR, Bilheimer DW, Brown DC, Dau PC, Gotto AM, Illingworth DR, Jones PH, Kelsey SF, Leitman SF, Stein EA, Stern TN, Zavoral JH, Zwiener J, for Liposorber Study Group (1991) Multicenter study of the treatment of familial hypercholesterolemia (FH) by LDL-apheresis using the liposorber LA-15 system (abstract). Arterioscler Thromb 11: 1409.Google Scholar
  42. 42.
    Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A and Goto Y for the LARS Investigators (1992) Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 95: 1–13.PubMedCrossRefGoogle Scholar
  43. 43.
    Greten H, Bleifeld W, Beil FU, Daerr W, Strauer BE, Kleophas W, Gries FA, Schuff-Werner P, Thiery J, Seidel D (1992) LDL-Apheresis. Ein therapeutisches Verfahren bei schwerer Hypercholesterinämie. Dtsch Arztebl Arztl Mitt 89(1/2): 48–49.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • D. Seidel

There are no affiliations available

Personalised recommendations